Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy



Status:Recruiting
Conditions:Renal Impairment / Chronic Kidney Disease
Therapuetic Areas:Nephrology / Urology
Healthy:No
Age Range:18 - Any
Updated:8/2/2018
Start Date:February 16, 2018
End Date:April 2023
Contact:Laura Haas
Email:lhaas@omeros.com
Phone:(206) 676-0886

Use our guide to learn which trials are right for you!

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)

The purpose of this study is to evaluate the safety and efficacy of OMS721 in patients with
IgA nephropathy. The study will assess proteinuria by 24-hour urine protein excretion (UPE)
in g/day at 24 weeks from beginning of treatment.

This is a Phase 3, double-blind, randomized, placebo-controlled, study in patients aged 18
years and above with a biopsy-confirmed diagnosis of IgAN and with 24-hour UPE that is > 1
g/day at baseline. During the study, all patients will continue optimized renin-angiotensin
system (RAS) blockade. The study consists of five periods: Screening, Run-In, Initial
Treatment (Weeks 1-12), Response Evaluation (Weeks 13-24), and Follow-Up (Weeks 25-144).
Patients are assessed for re-treatment based on their response to 24-hour UPE. Additional
treatment will be given to patients who relapse or who have partial response following the
Initial Treatment Period.

Approximately 430 patients are to enrolled in two groups of 215 patients per arm.

Inclusion Criteria:

- Age 18 years or older at the onset of Screening

- Biopsy confirmed diagnosis of IgAN within 10 years prior to Screening

- Proteinuria of > 1 g in 24-hour urine collection at Screening and baseline

- Estimated glomerular filtration rate of ≥ 30 and ≤ 90 mL/min/1.73 m2 at Screening and
baseline

- Currently on physician-directed, stable treatment with RAS blockade (ACEIs, ARBs,
direct renin inhibitors) and have a systolic BP of < 150 mmHg and a diastolic BP of <
100 mmHg at rest

Exclusion Criteria:

- Treatment with immunosuppressants (e.g., azathioprine or cyclophosphamide), cytotoxic
drugs, or eculizumab within 24 weeks prior to Screening

- Unwilling or unable to discontinue systemic corticosteroids 12 weeks prior to
Randomization

- Female patients who are pregnant, breast feeding, or planning to become pregnant up
through 12 weeks after the last dose of study drug, including possible retreatments

- Clinical or biological evidence of diabetes mellitus, systemic lupus erythematosus,
IgA vasculitis (Henoch-Schonlein purpura), secondary IgAN, or other renal disease

- History of renal transplantation

- Have a known hypersensitivity to any constituent of the investigational product

- Rapidly progressive glomerulonephritis

- Significant abnormalities in clinical laboratory values

- Body mass index ≥ 35 kg/m²

- History of human immunodeficiency virus (HIV), hepatitis B infection and hepatitis C
infection

- Diagnosis of a malignancy except for adequately treated and cured basal or squamous
cell skin cancer, curatively treated in situ disease, or other cancer from which the
patient has been disease-free for ≥ 5 years

- Have received any other investigational drug or device or experimental procedures
within 30 days of the Screening Visit (SV)
We found this trial at
18
sites
Boston, Massachusetts 02111
Phone: 206-676-0886
?
mi
from
Boston, MA
Click here to add this to my saved trials
Coral Gables, Florida 33134
Phone: 206-676-0886
?
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Florence, Alabama 35630
Phone: 206-676-0886
?
mi
from
Florence, AL
Click here to add this to my saved trials
Flushing, New York 11355
Phone: 206-676-0886
?
mi
from
Flushing, NY
Click here to add this to my saved trials
Fort Worth, Texas 76104
Phone: 206-676-0886
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Houston, Texas 77024
Phone: 206-676-0886
?
mi
from
Houston, TX
Click here to add this to my saved trials
Iowa City, Iowa 52242
Phone: 206-676-0886
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Kansas City, Missouri 64111
Phone: 206-676-0886
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Lawrenceville, Georgia 30046
Phone: 206-676-0886
?
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
Los Angeles, California 90025
Phone: 206-676-0886
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Mesa, Arizona 85210
Phone: 206-676-0886
?
mi
from
Mesa, AZ
Click here to add this to my saved trials
Miami Lakes, Florida 33014
Phone: 206-676-0886
?
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
Northridge, California 91324
Phone: 206-676-0886
?
mi
from
Northridge, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Phone: 206-676-0886
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Antonio, Texas 78215
Phone: 206-676-0886
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Seattle, Washington 98104
Phone: 206-676-0886
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Springfield, Massachusetts 01107
Phone: 206-676-0886
?
mi
from
Springfield, MA
Click here to add this to my saved trials
Torrance, California 90502
Phone: 206-676-0886
?
mi
from
Torrance, CA
Click here to add this to my saved trials